首页> 外文OA文献 >First-line FOLFIRI and bevacizumab in patients with advanced colorectal cancer prospectively stratified according to serum LDH: final results of the GISCAD (Italian Group for the Study of Digestive Tract Cancers) CENTRAL (ColorEctalavastiNTRiAlLdh) trial

【2h】

First-line FOLFIRI and bevacizumab in patients with advanced colorectal cancer prospectively stratified according to serum LDH: final results of the GISCAD (Italian Group for the Study of Digestive Tract Cancers) CENTRAL (ColorEctalavastiNTRiAlLdh) trial

机译：根据血清LDH前瞻性对晚期大肠癌患者的一线FOLFIRI和贝伐单抗进行分层：GISCAD（意大利消化道癌症研究小组）的最终结果CENTRAL（ColorEctalavastiNTRiAlLdh）试验

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

获取外文期刊封面目录资料

页面导航

摘要
著录项
引文网络
相似文献
相关主题

摘要

Previous findings suggested that bevacizumab might be able to improve response rate (RR) in colorectal cancer patients with high lactic dehydrogenase (LDH) basal levels.

机译：先前的研究结果表明，贝伐单抗可能能够提高具有高乳酸脱氢酶（LDH）基础水平的结直肠癌患者的缓解率（RR）。

著录项

作者
Giampieri, Riccardo; Puzzoni, Marco; Daniele, Bruno; Ferrari, Daris; Lonardi, Sara; Zaniboni, Alberto; Cavanna, Luigi; Rosati, Gerardo; Pella, Nicoletta; Zampino, Maria Giulia; Sozzi, Pietro; Germano, Domenico; Zagonel, Vittorina; Codecà, Carla; Libertini, Michela; Labianca, Roberto; Cascinu, Stefano; Scartozzi, Mario;
展开▼
作者单位

展开▼
年度 2017
总页数
原文格式 PDF
正文语种 eng
中图分类

相似文献

外文文献
中文文献

1. First-line FOLFIRI and bevacizumab in patients with advanced colorectal cancer prospectively stratified according to serum LDH: final results of the GISCAD (Italian Group for the Study of Digestive Tract Cancers) CENTRAL (ColorEctalavastiNTRiAlLdh) trial [J] . Riccardo Giampieri, Marco Puzzoni, Bruno Daniele, British Journal of Cancer . 2017,第8期

机译：根据血清LDH前瞻性对晚期大肠癌患者的一线FOLFIRI和贝伐单抗进行分层：GISCAD（意大利消化道癌研究小组）的最终结果CENTRAL（ColorEctalavastiNTRiAlLdh）试验
2. A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Pegfilgrastim in Patients Receiving First-Line FOLFOX/Bevacizumab or FOLFIRI/Bevacizumab for Locally Advanced or Metastatic Colorectal Cancer: Final Results of the Pegfilgrastim and Anti-VEGF Evaluation Study (PAVES) [J] . Pinter Tamas, Klippel Zandra, Cesas Alvydas, Clinical colorectal cancer . 2017,第2期

机译：在接受一线Folfox / Bevacizumab或Folfiri / BevacizumAb的患者中，PEGFILGRASIM的AII，随机，双盲，安慰剂对照试验，用于局部晚期或转移性结直肠癌：PEGFILGRASTIM和抗VEGF评估研究的最终结果（铺设）
3. Treatment sequence with either irinotecan/cetuximab followed by FOLFOX-4 or the reverse strategy in metastatic colorectal cancer patients progressing after first-line FOLFIRI/bevacizumab: An Italian Group for the Study of Gastrointestinal Cancer phase III, randomised trial comparing two sequences of therapy in colorectal metastatic patients [J] . European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR) . 2017,第期

机译：用伊立替康/西替昔单抗的治疗序列，然后进行Folfox-4或转移性结肠直肠癌患者的反向策略，在第一线Folfiri / Bevacizumab后进展：用于研究胃肠癌期III的意大利组，随机试验比较两种治疗序列结肠直肠转移性患者
4. Prospective Randomized Clinical Study on the Necessity of Chemical Cleaning in Patients with Colorectal Cancer [C] . T. Hone, M. Ishizuka, K. Takagi, Asian Federation of Coloproctology . 2005

机译：直肠癌患者化学清洁必要性的预期随机临床研究
5. Predictive factors of the treatment outcome in patients with advanced biliary tract cancer receiving gemcitabine plus cisplatin as first-line chemotherapy [D] . 鈴木, 裕子 2019

机译：吉西他滨联合顺铂一线化疗对晚期胆道癌患者治疗效果的预测因素
6. First-line FOLFIRI and bevacizumab in patients with advanced colorectal cancer prospectively stratified according to serum LDH: final results of the GISCAD (Italian Group for the Study of Digestive Tract Cancers) CENTRAL (ColorEctalavastiNTRiAlLdh) trial [O] . Riccardo Giampieri, Marco Puzzoni, Bruno Daniele, 2017

机译：根据血清LDH前瞻性对晚期大肠癌患者的一线FOLFIRI和贝伐单抗进行分层：GISCAD（意大利消化道癌症研究小组）的最终结果CENTRAL（ColorEctalavastiNTRiAlLdh）试验
7. Circulating pro-angiogenic markers in patients receiving first-line FOLFIRI + Bevacizumab. The SENTRAL (Serum angiogenesis-cENTRAL) pre-planned analysis of the Italian Research Group for Digestive Tract Cancer (GISCAD) CENTRAL trial (ColorEctalvastiNTRiAlLdh) [O] . R. Giampieri, M. Scartozzi, B. Daniele, 2016

机译：循环促血管生成标记物，接受第一线Folfiri + Bevacizumab的患者。 Sentral（血清血管生成 - 中央）对消化道癌症（GISCAD）中央试验（ColitectalvastridRialldh）的意大利研究组预计划分析

First-line FOLFIRI and bevacizumab in patients with advanced colorectal cancer prospectively stratified according to serum LDH: final results of the GISCAD (Italian Group for the Study of Digestive Tract Cancers) CENTRAL (ColorEctalavastiNTRiAlLdh) trial

摘要

著录项

引文网络

相似文献

相关主题

期刊订阅